While AnaptysBio Inc has overperformed by 2.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANAB rose by 280.14%, with highs and lows ranging from $49.90 to $12.21, whereas the simple moving average jumped by 91.94% in the last 200 days.
On October 13, 2025, Barclays started tracking AnaptysBio Inc (NASDAQ: ANAB) recommending Overweight. A report published by H.C. Wainwright on June 04, 2025, Upgraded its rating to ‘Buy’ for ANAB. Wolfe Research also rated ANAB shares as ‘Outperform’, setting a target price of $25 on the company’s shares in an initiating report dated February 04, 2025. H.C. Wainwright December 11, 2024d the rating to Neutral on December 11, 2024, and set its price target from $52 to $19. BTIG Research December 02, 2024d its ‘Buy’ rating to ‘Neutral’ for ANAB, as published in its report on December 02, 2024. H.C. Wainwright’s report from July 22, 2024 suggests a price prediction of $55 for ANAB shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of AnaptysBio Inc (ANAB)
Further, the quarter-over-quarter increase in sales is 154.26%, showing a positive trend in the upcoming months.
AnaptysBio Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -308.02% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.68, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ANAB has an average volume of 578.26K. On a monthly basis, the volatility of the stock is set at 6.30%, whereas on a weekly basis, it is put at 5.05%, with a gain of 10.47% over the past seven days. Furthermore, long-term investors anticipate a median target price of $65.09, showing growth from the present price of $50.33, which can serve as yet another indication of whether ANAB is worth investing in or should be passed over.
How Do You Analyze AnaptysBio Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 6.54%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 112.61% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
